Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2008 by Karolinska University Hospital.
Recruitment status was:  Active, not recruiting
Ministry of Health and Social Affairs, Sweden
County of Stockholm
Information provided by:
Karolinska University Hospital Identifier:
First received: July 30, 2008
Last updated: NA
Last verified: July 2008
History: No changes posted

July 30, 2008
July 30, 2008
January 2008
December 2009   (Final data collection date for primary outcome measure)
The primary outcome will be self-reported pleasurable opiate effect. [ Time Frame: One week ]
Same as current
No Changes Posted
The secondary outcome will be physiological opiate responses. [ Time Frame: One week ]
Same as current
Not Provided
Not Provided
Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers
Modulation of Opiate Reward by NK1 Antagonism: A Laboratory-Based Proof of Concept Study
The objective of this study is to determine whether aprepitant blocks the opiate reward system in non-dependent opiate abusers, indicating its potential as a safe, non-addictive first line therapy for early heroin abuse.
This initial proof-of-concept study focuses on evaluating whether an NK1 antagonist, aprepitant, can block opiate reward in non-dependent opiate experienced volunteers in response to a standard opiate challenge. Sixty subjects will be included in a randomized controlled study. Following a training challenge session, they will receive 1 week treatment with aprepitant or matching placebo, followed by a challenge session during which subjective and physiological responses to the opiate partial agonist buprenorphine will be assessed.
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
  • Opioid-Related Disorders
  • Heroin Dependence
  • Substance-Related Disorders
  • Drug: aprepitant
    Oral, 125 mg once daily for one week
    Other Name: Emend
  • Drug: Pseudo-placebo - buprenorphine
    Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
    Other Name: Subutex
  • Experimental: 1
    Intervention: Drug: aprepitant
  • Placebo Comparator: 2
    Intervention: Drug: Pseudo-placebo - buprenorphine
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
June 2010
December 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18 - 50
  • Current opiate use, without dependence

Exclusion Criteria:

  • Clinical diagnosis of opiate dependence
  • Positive urine screen for opiates on day of challenge sessions
  • Meet diagnostic criteria for any other substance abuse disorder except nicotine within the last 12 months.
  • Any ongoing prescription medication other than oral contraceptives or hormone replacement
  • Any serious medical condition which in the judgment of the investigators makes administration of opiates medically inappropriate.
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Aprepitant 1
Not Provided
Not Provided
Not Provided
Markus Heilig, MD, PhD, Karolinska Universitetssjukhuset
Karolinska University Hospital
  • Ministry of Health and Social Affairs, Sweden
  • County of Stockholm
Principal Investigator: Markus Heilig, MD, PhD Karolinska Universitetssjukhuset
Study Director: Johan Kakko, MD Karolinska Universitetssjukhuset
Karolinska University Hospital
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP